Human AGTR1, ACE, ADRB1, CYP2D6, CYP2C9 Gene Detection Kit (PCR-Fluorescent Probe Method) has obtained the registration certificate of Class III from NMPA.
After SLCO1B1&APOE, CYP2C19, MTHFR, ALDH2 and CYP2C9&VKOC1 gene detection kit, the company has gained another Class III certificate of pharmacogenomics.
Product Characteristics
This kit is suitable for the qualitative detection of AGTR1, ACE, ADRB1, CYP2D6 and CYP2C9 gene polymorphisms in the DNA of human whole blood samples, which can assist in guiding the personalized dosing of hypertension,including β-blockers, angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin II receptor antagonists (ARBs).
Product Advantages:
① Higher throughput
② Open reagent
③ Simple judgement
④ Anti-pollution system
⑤ Lower detection limit 0.5ng/μL.
Background of hypertension medication
Hypertension is a major factor in the incidence of stroke and coronary heart disease and death in China, and the prevalence of hypertension in China has shown a significant increase over the past 50 years. For the treatment of hypertension, a variety of antihypertensive drugs are usually taken at the same time in order to achieve better antihypertensive effects. Antihypertensive drugs commonly used in clinical practice include angiotensin II receptor antagonists (ARBs), angiotensin-converting enzyme inhibitors (ACEIs), beta-blockers, thiazide diuretics, and calcium channel blockers (CCBs).
The choice of drugs with anti-hypertensive mechanisms that can reduce the side effects of hypertensive drugs and at the same time improve the effectiveness of the drugs has always been of great clinical interest. Clinical practice has revealed that there are individualized differences in the response of different patients to the drug for the same anti-hypertensive drug, and genetic polymorphism is an important factor influencing the personalized differences in drug response.
